Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Background: The majority of studies that provide insights into the influence of the microbiome on the health of hematologic malignancy patients have concentrated on the transplant setting. Here, we sought to assess the predictive capacity of the gastrointestinal microbiome and its relationship to infectious outcomes in patients with acute myeloid leukemia (AML). Methods: 16s rRNA-based analysis was performed on oral swabs and stool samples obtained biweekly from baseline until neutrophil recovery following induction chemotherapy (IC) in 97 AML patients. Microbiome characteristics were correlated with clinical outcomes both during and after IC completion. Results: At the start of IC, higher stool Shannon diversity (hazard ratio [HR], 0.36; 95% confidence interval [CI], .18–.74) and higher relative abundance of Porphyromonadaceae (HR, 0.36; 95% CI, .18–.73) were associated with increased probability of remaining infection-free during neutropenia. A baseline stool Shannon diversity cutoff of <2 had optimal operating characteristics for predicting infectious complications during neutropenia. Although 56 patients received therapy >72 hours with a carbapenem, none of the patients had an infection with an extended spectrum β-lactamase–producing organism. Patients who received carbapenems for >72 hours had significantly lower α-diversity at neutrophil recovery (P = .001) and were approximately 4 times more likely to have infection in the 90 days following neutrophil recovery (HR, 4.55; 95% CI, 1.73–11.93). Conclusions: Our results suggest that gut microbiome evaluation could assist with infectious risk stratification and that improved targeting of antibiotic administration during IC could decrease subsequent infectious complications in AML patients. Baseline microbiome diversity is a strong independent predictor of infection during acute myeloid leukemia induction chemotherapy (IC) among clinical and microbiome covariates. Higher baseline levels of Porphyromonadaceae appear protective against infection, while carbapenem use is associated with consequences to the microbiome and infection susceptibility post-IC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These antibiotics exert a considerable broad-spectrum, anti-pseudomonal activity, and are also known to severely disrupt the gut microbiome by targeting many anaerobic commensals10,26.”
From A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy (2023) · cites this paper as [26]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 2×
“Adjustment for multiple hypothesis testing was done within each taxonomy level by adjusting for false discovery rate using the BenjaminiHochberg (BH) method [31].”
MethodThe SILVA ribosomal RNA gene database project: improved data processing and web-based tools
Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., & Glöckner, F. O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1219 · Cited by 33,055 · cited 1×
“Sequences were assigned to operational taxonomic units at 97% sequence similarity using the UPARSE pipeline and aligned to the SILVA SSURef_NR99_119 database with calculations of α- and β-diversity metrics of microbiome communities conducted in R using the Phyloseq package as previously described [17, 21, 26, 27].”
Methodphyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data
McMurdie, P. J., & Holmes, S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061217 · Cited by 21,322 · cited 1×
“Sequences were assigned to operational taxonomic units at 97% sequence similarity using the UPARSE pipeline and aligned to the SILVA SSURef_NR99_119 database with calculations of α- and β-diversity metrics of microbiome communities conducted in R using the Phyloseq package as previously described [17, 21, 26, 27].”
MethodStructure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
nlme : Linear and nonlinear mixed effects models
DebRoy, S. (2006) · Medical Entomology and Zoology · Cited by 10,009
Hanley, J. A., & McNeil, B. J. (1983) · Radiology · doi:10.1148/radiology.148.3.6878708 · Cited by 7,016 · cited 1×
“A receiver operating characteristic (ROC) curve and the corresponding area under the curve (AUC) value was calculated for baseline stool Shannon diversity predicting infection during IC [32, 33].”
MethodFreifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
A framework for human microbiome research
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11209 · Cited by 2,650
Dichotomizing continuous predictors in multiple regression: a bad idea
Royston, P., Altman, D. G., & Sauerbrei, W. (2006) · Statistics in Medicine · doi:10.1002/sim.2331 · Cited by 2,312 · cited 1×
“Given there are known statistical issues when dichotomizing continuous covariates in multiple regressions [41], covariates were analyzed as both binary and continuous in separate multivariable models where covariates with the FDRadjusted P value <0.”
Methodsurvminer: Drawing Survival Curves using 'ggplot2'
Kassambara, A., Kosinski, M., & Biecek, P. (2016) · CRAN: Contributed Packages · doi:10.32614/cran.package.survminer · Cited by 1,177
Taur, Y., Xavier, J. B., Lipuma, L., Ubeda, C., Goldberg, J., Gobourne, A., Lee, Y. J., Dubin, K. A., Socci, N. D., Viale, A., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis580 · Cited by 1,020
Self-citationTaur, Y., Jenq, R. R., Perales, M.-A., Littmann, E. R., Morjaria, S., Ling, L., No, D., Gobourne, A., Viale, A., Dahi, P. B., et al. (2014) · Blood · doi:10.1182/blood-2014-02-554725 · Cited by 885 · cited 1×
“Taur et al previously found β-lactam receipt to be associated with mortality following HSCT and suggested that the effects of β-lactam receipt could be summarized in decreased intestinal diversity [10].”
BackgroundSelf-citationReceiver operating characteristic (ROC) methodology: the state of the art.
Hanley, J. A. (1989) · PubMed · Cited by 807
Forest plots: trying to see the wood and the trees
Lewis, S., & Clarke, M. (2001) · BMJ · doi:10.1136/bmj.322.7300.1479 · Cited by 763 · cited 1×
“AML Microbiome Biomarkers for Infection • cid 2020:71 (1 July) • 65 indices predicting infection prior to neutrophil recovery [34].”
BackgroundIntestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease
Jenq, R. R., Taur, Y., Devlin, S. M., Ponce, D. M., Goldberg, J. D., Ahr, K. F., Littmann, E. R., Ling, L., Gobourne, A. C., Miller, L. C., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2015.04.016 · Cited by 748
Self-citationFreifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq147 · Cited by 704
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
Bucaneve, G., Micozzi, A., Menichetti, F., Martino, P., Dionisi, M. S., Martinelli, G., Allione, B., D'Antonio, D., Buelli, M., Nosari, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044097 · Cited by 648
Statistics review 12: survival analysis.
Bewick, V., Cheek, L., & Ball, J. (2004) · Critical Care · doi:10.1186/cc2955 · Cited by 516 · cited 2×
“Kaplan-Meier curves were used to visualize time to infection based on “high” and “low” abundance or diversity groups (above and below the median) for different covariates [35].”
MethodUbeda, C., Bucci, V., Caballero, S., Djukovic, A., Toussaint, N. C., Equinda, M., Lipuma, L., Ling, L., Gobourne, A., No, D., et al. (2013) · Infection and Immunity · doi:10.1128/iai.01197-12 · Cited by 466 · cited 1×
“Specifically, we found that increased baseline levels of Porphyromonadaceae were protective against subsequent infectious episodes, perhaps due to the active role in colonization resistance against pathogens previously demonstrated for members of this family, such as Barnesiella [43] (Figures 2 and 3, Table 2).”
BackgroundSelf-citationPower and sample-size estimation for microbiome studies using pairwise distances and PERMANOVA
Kelly, B. J., Gross, R., Bittinger, K., Sherrill-Mix, S., Lewis, J. D., Collman, R. G., Bushman, F. D., & Li, H. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv183 · Cited by 454 · cited 3×
“Differences in community structure between baseline and end-of-study were visualized using principal coordinate analysis (PCoA) of Bray-Curtis distances, with the P value and R2 (the coefficient of determination) determined by PERMANOVA [29].”
MethodInfluentialIntestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation
Peled, J. U., Devlin, S. M., Staffas, A., Lumish, M., Khanin, R., Littmann, E. R., Ling, L., Kosuri, S., Maloy, M., Slingerland, J. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3348 · Cited by 325
Self-citationRisk of mortality in patients with cancer who experience febrile neutropenia
Lyman, G. H., Michels, S. L., Reynolds, M. W., Barron, R., Tomic, K. S., & Yu, J. (2010) · Cancer · doi:10.1002/cncr.25332 · Cited by 246
Aguilar-Guisado, M., Espigado, I., Martín-Peña, A., Gudiol, C., Royo-Cebrecos, C., Falantes, J., Vázquez-López, L., Montero, M. I., Rosso-Fernández, C., de la Luz Martino, M., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30211-9 · Cited by 244
Infections in Patients with Febrile Neutropenia: Epidemiology, Microbiology, and Risk Stratification
Viscoli, C., Varnier, O., & Machetti, M. (2005) · Clinical Infectious Diseases · doi:10.1086/427329 · Cited by 239
Sung, L., Lange, B. J., Gerbing, R. B., Alonzo, T. A., & Feusner, J. (2007) · Blood · doi:10.1182/blood-2007-05-091942 · Cited by 231
Therneau, T. M. (2001) · CRAN: Contributed Packages · doi:10.32614/cran.package.survival · Cited by 229
Bloodstream infections in neutropenic cancer patients: A practical update
Gustinetti, G., & Mikulska, M. (2016) · Virulence · doi:10.1080/21505594.2016.1156821 · Cited by 205
Golob, J. L., Pergam, S. A., Srinivasan, S., Fiedler, T. L., Liu, C., Garcia, K., Mielcarek, M., Ko, D., Aker, S., Marquis, S., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix699 · Cited by 201
Weber, D., Oefner, P. J., Hiergeist, A., Koestler, J., Gessner, A., Weber, M., Hahn, J., Wolff, D., Stämmler, F., Spang, R., et al. (2015) · Blood · doi:10.1182/blood-2015-04-638858 · Cited by 195
Hakim, H., Dallas, R., Wolf, J., Tang, L., Schultz-Cherry, S., Darling, V., Johnson, C., Karlsson, E. A., Chang, T.-C., Jeha, S., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy153 · Cited by 192 · cited 1×
“70 • cid 2020:71 (1 July) • Galloway-Peña et al neutropenia in pediatric ALL but did not find baseline gut Shannon diversity to be significantly correlated with infection [18].”
BackgroundPretreatment gut microbiome predicts chemotherapy-related bloodstream infection
Montassier, E., Al-Ghalith, G. A., Ward, T., Corvec, S., Gastinne, T., Potel, G., Moreau, P., de la Cochetiere, M. F., Batard, E., & Knights, D. (2016) · Genome Medicine · doi:10.1186/s13073-016-0301-4 · Cited by 188 · cited 1×
“In agreement with our findings, patients with non-Hodgkin lymphoma undergoing HSCT who developed subsequent bloodstream infection exhibited reduced gut microbial diversity prior to chemotherapy [19].”
ResultGalloway‐Peña, J. R., Smith, D. P., Sahasrabhojane, P., Ajami, N. J., Wadsworth, W. D., Daver, N. G., Chemaly, R. F., Marsh, L., Ghantoji, S. S., Pemmaraju, N., et al. (2016) · Cancer · doi:10.1002/cncr.30039 · Cited by 188 · cited 7×
“We previously determined that the baseline diversity of the gut microbiome was significantly associated with infectious risk during induction chemotherapy (IC) for acute myeloid leukemia (AML) in a small cohort (N = 34) [17].”
BackgroundMethodResultInfluentialSelf-citationSimms-Waldrip, T. R., Sunkersett, G., Coughlin, L. A., Savani, M. R., Arana, C., Kim, J., Kim, M., Zhan, X., Greenberg, D. E., Xie, Y., et al. (2017) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2017.02.004 · Cited by 175
Characterization of oral and gut microbiome temporal variability in hospitalized cancer patients
Galloway-Peña, J. R., Smith, D. P., Sahasrabhojane, P., Wadsworth, W. D., Fellman, B. M., Ajami, N. J., Shpall, E. J., Daver, N., Guindani, M., Petrosino, J. F., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0409-1 · Cited by 112 · cited 4×
“Study patients consisted of 97 newly diagnosed adult AML patients undergoing IC at MD Anderson Cancer Center (MDACC) in Houston, Texas, from September 2013 to August 2015, in which subsets of patients were also previously analyzed (Table 1) [17, 21].”
MethodInfluentialSelf-citationRangaraj, G., Granwehr, B. P., Jiang, Y., Hachem, R. Y., & RAAD, I. I. (2010) · Cancer · doi:10.1002/cncr.24812 · Cited by 109 · cited 1×
“Consequently, there is a subset of hematologic malignancy patients who do not benefit from antimicrobial prophylaxis amid the ongoing concern regarding emergence of antimicrobial-resistant bacteria in both clinical specimens and fecal samples in patients receiving prophylaxis [46, 47].”
BackgroundEvaluation of New Anti-Infective Drugs for the Treatment of Febrile Episodes in Neutropenic Patients
Hughes, W. T., Pizzo, P. A., Wade, J. C., Armstrong, D., Webb, C. D., & Young, L. S. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.supplement_1.s206 · Cited by 95
Microbiome mediation of infections in the cancer setting
Taur, Y., & Pamer, E. G. (2016) · Genome Medicine · doi:10.1186/s13073-016-0306-z · Cited by 89 · cited 1×
“As currently understood, most infections result from translocation of pathogenic bacteria across damaged intestinal mucosa, leading to subsequent bacteremia [15, 16].”
BackgroundBuckley, S. A., Othus, M. K. D., Vainstein, V., Abkowitz, J. L., Estey, E. H., & Walter, R. B. (2014) · American Journal of Hematology · doi:10.1002/ajh.23661 · Cited by 85
Liu, C., Frank, D. N., Horch, M., Chau, S., Ir, D., Horch, E. A., Tretina, K., van Besien, K., Lozupone, C., & Nguyen, V. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.200 · Cited by 77
Nearing, J. T., Connors, J., Whitehouse, S., Limbergen, J. V., MacDonald, T., Kulkarni, K. P., & Langille, M. G. I. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00028 · Cited by 72
Mancini, N., Greco, R., Pasciuta, R., Barbanti, M. C., Pini, G., Morrow, O. B., Morelli, M., Vago, L., Clementi, N., Giglio, F., et al. (2017) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofx215 · Cited by 71 · cited 6×
“Mancini et al found that the abundance of specific microbes, not Shannon diversity, at preconditioning was associated with gram-negative septicemia following HSCT [5].”
BackgroundInfluentialCannas, G., Pautas, C., Raffoux, E., Quesnel, B., de Botton, S., de Revel, T., Reman, O., Gardin, C., Elhamri, M., Boissel, N., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.636812 · Cited by 70 · cited 1×
“In addition to suffering high rates of infection during IC, AML patients also have a high infectious burden during consolidation therapy post-IC [42].”
Backgroundla Martire, G., Robin, C., Oubaya, N., Lepeule, R., Beckerich, F., Leclerc, M., Barhoumi, W., Toma, A., Pautas, C., Maury, S., et al. (2018) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-018-3328-1 · Cited by 70 · cited 1×
“For example, deescalation and discontinuation strategies to reduce the level of carbapenem consumption resulted in no difference in rates of intensive care unit transfers, bacteremia, or mortality [50].”
BackgroundDoki, N., Suyama, M., Sasajima, S., Ota, J., Igarashi, A., Mimura, I., Morita, H., Fujioka, Y., Sugiyama, D., Nishikawa, H., et al. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3069-8 · Cited by 60
Impact of the Microbiota on Bacterial Infections during Cancer Treatment
Galloway-Peña, J., Brumlow, C., & Shelburne, S. A. (2017) · Trends in Microbiology · doi:10.1016/j.tim.2017.06.006 · Cited by 57 · cited 2×
“As currently understood, most infections result from translocation of pathogenic bacteria across damaged intestinal mucosa, leading to subsequent bacteremia [15, 16].”
BackgroundSelf-citationGustinetti, G., Raiola, A. M., Varaldo, R., Galaverna, F., Gualandi, F., Bono, V. D., Bacigalupo, A. P., Angelucci, E., Viscoli, C., & Mikulska, M. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.03.018 · Cited by 53
Huang, C.-T., Liu, C.-J., Ko, P.-S., Liu, H.-T., Yu, Y.-B., Hsiao, L.-T., Gau, J.-P., Tzeng, C.-H., Chiou, T.-J., Liu, J.-H., et al. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-016-2155-1 · Cited by 39
Rosa, R. G., Goldani, L. Z., & dos Santos, R. P. (2013) · American Journal of Infection Control · doi:10.1016/j.ajic.2013.06.025 · Cited by 31
Wong, M. S. Y., Barqasho, B., Öhrmalm, L., Tolfvenstam, T., & Nowak, P. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068056 · Cited by 16 · cited 1×
“Although the majority of infections in hematologic malignancy patients are derived from gastrointestinal flora [44], few studies have explored baseline gut microbiome composition and its association with infectious outcomes during adult leukemia chemotherapy [15].”
BackgroundChong, Y., Shimoda, S., Miyake, N., Aoki, T., Ito, Y., Kamimura, T., & Shimono, N. (2017) · Infection and Drug Resistance · doi:10.2147/idr.s133333 · Cited by 14 · cited 1×
“Consequently, there is a subset of hematologic malignancy patients who do not benefit from antimicrobial prophylaxis amid the ongoing concern regarding emergence of antimicrobial-resistant bacteria in both clinical specimens and fecal samples in patients receiving prophylaxis [46, 47].”
Background
Research works printed but not linked: 1
- 30. Alkek Center for Metagenomics and Microbiome Research. ATIMA (Agile toolKit for Inclusive Microbial Analyses) 2019. Available at: https://cmmr.shinyapps.io/atima2/ [Google Scholar]
Cited by
Stein-Thoeringer, C. K., Saini, N. Y., Zamir, E., Blumenberg, V., Schubert, M.-L., Mor, U., Fante, M. A., Schmidt, S., Hayase, E., Hayase, T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02234-6 · Cited by 255
Self-citationWang, R., Yang, X., Liu, J., Zhong, F., Zhang, C., Chen, Y., Sun, T., Ji, C., & Ma, D. (2022) · Nature Communications · doi:10.1038/s41467-022-30240-8 · Cited by 226
Wei, L., Wen, X.-S., & Xian, C. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179474 · Cited by 151
“The authors suggested that intestinal microbiome evaluation could help with infectious risk stratification to decrease subsequent infectious complications in ALL patients [23].”
BackgroundMalard, F., Vekhoff, A., Lapusan, S., Isnard, F., D’Incan, E., Rey, J., Saillard, C., Thomas, X., Ducastelle-Leprêtre, S., Paubelle, É., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23376-6 · Cited by 115
Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure
Uribe‐Herranz, M., Klein-González, N., Rodríguez‐Lobato, L. G., Juan, M., & de Larrea, C. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031026 · Cited by 88
Metadata
- Authors
- Galloway-Peña, J. R., Shi, Y., Peterson, C. B., Sahasrabhojane, P., Gopalakrishnan, V., Brumlow, C. E., Daver, N. G., Alfayez, M., Boddu, P. C., Khan, M. A. W., Wargo, J. A., Do, K.-A., Jenq, R. R., Kontoyiannis, D. P., & Shelburne, S. A.
- Affiliations
- Department of Genomic Medicine, Houston, Texas, USA
- Department of Biostatistics, Houston, Texas, USA
- Department of Infectious Disease, Infection Control, and Employee Health, Houston, Texas, USA
- Department of Surgical Oncology, Houston, Texas, USA
- The University of Texas MD Anderson Cancer Center (US)
- Yale University (US)
- Corresponding author
- Shelburne, Samuel A
- ORCID
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-08-22
- Volume
- 71
- Issue
- 1
- Pages
- 63-71
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC7312220
- OpenAlex
- W2969463435
- Cited by
- 140
- References
- 50
- Citations by year
- 2026: 24 · 2025: 32 · 2024: 18 · 2023: 24 · 2022: 14 · 2021: 20 · 2020: 8
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- MD Anderson Cancer Center
- Anderson Odyssey Fellowship Program
- National Institute of Allergy and Infectious Diseases (1 K01 AI143881-01)
- National Cancer Institute (P30CA016672, R01 CA219896-01A1)
- United States-Israel Binational Science Foundation (201332)
- Kennedy Memorial Foundation (0727030)
- American Association for Cancer Research Stand Up To Cancer (SU2C-AACR-IRG-19-17)
- Department of Defense (W81XWH-16-1-0121)
- Andrew Sabin Family Fellows Program
- Texas 4000 Distinguished Professorship
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- gut microbiota, acute myeloid leukemia, induction chemotherapy, infectious disease risk, neutropenia, Porphyromonadaceae, microbial diversity, carbapenem use, extended-spectrum beta-lactamase, infection prediction, antibiotic stewardship, neutrophil recovery
- MeSH terms
- Gastrointestinal Microbiome, Feces, Humans, RNA, Ribosomal, 16S, Leukemia, Myeloid, Acute, Induction Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.